Keyphrases
Long-term Survival
100%
Survival Analysis
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Androgen Deprivation Therapy
100%
Chemohormonal Therapy
100%
Hazard Ratio
60%
Overall Survival
40%
Median Overall Survival
40%
Docetaxel
40%
Overall Survival Benefit
40%
Low Volume Disease
40%
Randomized Trial
20%
Prostate Cancer
20%
Phase II Study
20%
Pelvis
20%
Cancer Clinical Trials
20%
Tumor Volume
20%
Bone Metastasis
20%
Extensive Disease
20%
Clinical Benefit
20%
Vertebral Column
20%
Androgen Ablation
20%
Visceral Metastases
20%
Low Volume
20%
CHAARTED
20%
Medicine and Dentistry
Prostate Cancer
100%
Long Term Survival
100%
Survival Analysis
100%
Diseases
100%
Overall Survival
85%
Androgen Deprivation Therapy
71%
Hazard Ratio
42%
Docetaxel
28%
Neoplasm
14%
Arm
14%
Pelvis
14%
Bone Metastasis
14%
Androgen
14%
Visceral Metastasis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Long Term Survival
100%
Diseases
100%
Overall Survival
85%
Androgen
85%
Docetaxel
28%
Neoplasm
14%
Bone Metastasis
14%
Visceral Metastasis
14%
Neuroscience
Androgen
100%
Survival Analysis
100%
Prostate
100%
Docetaxel
33%
Pelvis
16%
Vertebral Column
16%